Dr. James Cox, Medical Director for ATS Medical, To Present at TCT Surgeon Session

The first presentation by Dr. Cox is entitled "Sutureless Surgical Aortic Valve Replacement: The Enable Valve." The ATS Enable(R) Aortic Bioprosthesis is the same valve as the traditionally sutured ATS 3f(R) Aortic Bioprosthesis, but mounted on a Nitinol self-expanding frame. The ATS 3f Enable eliminates the need for traditional suturing of aortic replacement valves, saving valuable cardiopulmonary bypass and aortic cross clamp time providing surgeons and patients with a minimally invasive alternative to traditional open chest procedures.

Dr. Cox, the original founder of the Maze procedure, will also present "Surgical Options and Results for Atrial Fibrillation: Historical Overview and Current Approaches." As the Medical Director for ATS, Dr. Cox was instrumental in the development of the ATS CryoMaze(R) Clamp which was recently launched in the US. He has hosted several ATS educational symposia, bringing together the thought leaders in the surgical treatment of AF and he is the architect of the Company's world class AF advisory board.

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 160,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007 and its most recent quarterly report on Form 10-Q.

SOURCE ATS Medical, Inc.

Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze, Daily News

Tags: ,HEA,MTC,TDS,MN-ATSsurgeon-session

   _   _

           

Is your favorite bookmark site missing? Ask for it.